J. Steinbrecher

A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC).

H. Scher, C. Redfern, E. Antonarakis, 2012 .

Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study.

S. Larson, M. Morris, H. Scher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two-stage Exchange Knee Arthroplasty: Does Resistance of the Infecting Organism Influence the Outcome?

Javad Parvizi, J. Parvizi, Mark F. Kurd, 2010, Clinical orthopaedics and related research.

Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study.

S. Larson, M. Morris, H. Scher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC).

S. Larson, M. Morris, H. Scher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.